The GMZ2 malaria vaccine: from concept to efficacy in humans
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
The GMZ2 malaria vaccine: from concept to efficacy in humans. / Theisen, Michael; Adu, Bright; Mordmueller, Benjamin; Singh, Subhash.
I: Expert Review of Vaccines, Bind 16, Nr. 9, 2017, s. 907-917.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The GMZ2 malaria vaccine: from concept to efficacy in humans
AU - Theisen, Michael
AU - Adu, Bright
AU - Mordmueller, Benjamin
AU - Singh, Subhash
PY - 2017
Y1 - 2017
N2 - Introduction: GMZ2 is a recombinant protein consisting of conserved domains of GLURP and MSP3, two asexual blood-stage antigens of Plasmodium falciparum, and is designed with the aim of mimicking naturally acquired anti-malarial immunity. The rationale for combining these two antigens is based on a series of immune epidemiological studies from geographically diverse malaria endemic regions; functional in vitro studies; and pre-clinical studies in rodents and New World monkeys. GMZ2 adjuvanted with alhydrogel® (alum) was well tolerated and immunogenic in three phase 1 studies. The recently concluded phase 2 trial of GMZ2/alum, involving 1849 participants 12 to 60 month of age in four countries in West, Central and Eastern Africa, showed that GMZ2 is well tolerated and has some, albeit modest, efficacy in the target population.Areas covered: PubMed (www.ncbi.nlm.nih.gov/pubmed) was searched to review the progress and future prospects for clinical development of GMZ2 sub-unit vaccine. We will focus on discovery, naturally acquired immunity, functional activity of specific antibodies, sequence diversity, production, pre-clinical and clinical studies.Expert commentary: GMZ2 is well tolerated and has some, albeit modest, efficacy in the target population. More immunogenic formulations should be developed.
AB - Introduction: GMZ2 is a recombinant protein consisting of conserved domains of GLURP and MSP3, two asexual blood-stage antigens of Plasmodium falciparum, and is designed with the aim of mimicking naturally acquired anti-malarial immunity. The rationale for combining these two antigens is based on a series of immune epidemiological studies from geographically diverse malaria endemic regions; functional in vitro studies; and pre-clinical studies in rodents and New World monkeys. GMZ2 adjuvanted with alhydrogel® (alum) was well tolerated and immunogenic in three phase 1 studies. The recently concluded phase 2 trial of GMZ2/alum, involving 1849 participants 12 to 60 month of age in four countries in West, Central and Eastern Africa, showed that GMZ2 is well tolerated and has some, albeit modest, efficacy in the target population.Areas covered: PubMed (www.ncbi.nlm.nih.gov/pubmed) was searched to review the progress and future prospects for clinical development of GMZ2 sub-unit vaccine. We will focus on discovery, naturally acquired immunity, functional activity of specific antibodies, sequence diversity, production, pre-clinical and clinical studies.Expert commentary: GMZ2 is well tolerated and has some, albeit modest, efficacy in the target population. More immunogenic formulations should be developed.
KW - Malaria
KW - naturally acquired immunity
KW - vaccine
KW - cytophilic IgG
KW - GMZ2
KW - GLURP
KW - MSP3
U2 - 10.1080/14760584.2017.1355246
DO - 10.1080/14760584.2017.1355246
M3 - Journal article
C2 - 28699823
VL - 16
SP - 907
EP - 917
JO - Expert Review of Vaccines
JF - Expert Review of Vaccines
SN - 1476-0584
IS - 9
ER -
ID: 182580561